<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Filgrastim</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00099</strong>&#160; (BIOD00072, BTD00072)</td></tr><tr><th>Type</th><td>biotech</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Filgrastim is a recombinant, non-pegylated human granulocyte colony stimulating factor (G-<span class="caps">CSF</span>) analogue manufactured by recombinant <span class="caps">DNA</span> technology using a strain of E. coli. It is marketed as the brand name Neupogen by Amgen. Chemically, it consists of 175 amino acid residues. The protein has an amino acid sequence that is identical to the natural sequence predicted from human <span class="caps">DNA</span> sequence analysis, except for the addition of an N-terminal methionine necessary for expression in E coli. Tbo-filgrastim, which is marketed by Sicor Biotech and <span class="caps">FDA</span> approved on August 29, 2012, contains the same active ingredient as Neupogen and is biologically similar, but it is formulated to be short-acting.</p></td></tr><tr><th>Protein structure</th><td><a href="/system/protein_structures/full/DB00099.png?1266600389"><img alt="Db00099" src="/system/protein_structures/thumb/DB00099.png?1266600389"></a></td></tr><tr><th>Protein chemical formula</th><td>C<sub>845</sub>H<sub>1343</sub>N<sub>223</sub>O<sub>243</sub>S<sub>9</sub></td></tr><tr><th>Protein average weight</th><td>18.8 kDa</td></tr><tr><th>Sequences</th><td><pre class="sequence">&gt;Amino acid sequence for filgrastim
MTPLGPASSLPQSFLLKCLEQVRKIQGDGAALQEKLCATYKLCHPEELVLLGHSLGIPWA
PLSSCPSQALQLAGCLSQLHSGLFLYQGLLQALEGISPELGPTLDTLQLDVADFATTIWQ
QMEELGMAPALQPTQGAMPAFASAFQRRAGGVLVASHLQSFLEVSYRVLRHLAQP</pre><small><a class="btn btn-info btn-sm" href="/drugs/DB00099/polypeptide_sequences.fasta">Download FASTA Format</a></small></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>G-CSF </td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Granulocyte Colony Stimulating Factor </td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Tbo-filgrastim</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Biocilin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Biofigran</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Biofilgran</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Endufil</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Filatil</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Filgen</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Gran</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>GRANIX</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Granulokine</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Grimatin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Inmunef</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Jiexin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Leucogen</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Leucostim</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Macroleuco</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Neukine</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Neupogen</td><td>Amgen Inc.</td></tr><tr><td>Neutromax</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Neutroval </td><td>Sicor Biotech</td></tr><tr><td>Nivestim</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Recombicyte</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>SciLocyte</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Tevagastrim</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>White-C </td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Zarzio</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/immunosuppressive-agents">Immunosuppressive Agents</a></li>
<li><a href="/mesh/antineutropenic-agents">Antineutropenic Agents</a></li>
<li><a href="/mesh/hematopoietic-agents">Hematopoietic Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>121181-53-1</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Organic Acids</td></tr><tr><th>Class</th><td>Carboxylic Acids and Derivatives</td></tr><tr><th>Subclass</th><td>Amino Acids, Peptides, and Analogues</td></tr><tr><th>Direct parent</th><td>Peptides</td></tr><tr><th>Alternative parents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Substituents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Classification description</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Filgrastim is used in patients with acute myeloid leukemia receiving induction or consolidation chemotherapy. It is also used in cancer patients receiving bone marrow transplant. In general, filgrastim increases neutrophil counts in order to decrease the risk of infection or duration of neutropenia in the aforementioned patient populations. Infection and neutropenia are adverse events associated with chemotherapy. Furthermore, filgrastim is also indicated for patients with severe chronic neutropenia. It mobilizes hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis to allow for a more rapid engraftment. Tbo-filgrastim has a narrower indication profile than Neupogen - it is a leukocyte growth factor indicated for the reduction in the duration of severe neutropenia in patients with non-myeloid malignancies.</td></tr><tr><th>Pharmacodynamics</th><td>Used in the treatment of chemotherapy-induced neutropenia by enhancing the production of neutrophils. Filgrastim acts on hematopoietic cells by binding to specific cell surface receptors thereby stimulating proliferation, differentiation, commitment, and end cell functional activation. When tbo-filgrastim is administered to cancer patients, it took 3-5 days to reach maximum absolute neutrophil count (ANC). Levels of neutrophils returned to baseline by 21 days following completion of chemotherapy. In the healthy volunteer trials, doubling the tbo-filgrastim subcutaneous dose from 5 to 10 mcg/kg resulted in a 16-19% increase in the ANCmax and a 33-36% increase in the area under the effect curve for ANC.  </td></tr><tr><th>Mechanism of action</th><td>Filgrastim binds to the G-CSF receptor and stimulates the production of neutrophils in the bone marrow. As a G-CSF analog, it controls proliferation of committed progenitor cells and influences their maturation into mature neutrophils. Filgrastim also stimulates the release of neutrophils from bone marrow storage pools and reduces their maturation time. Filgrastim acts to increase the phagocytic activity of mature neutrophils. In patients receiving cytotoxic chemotherapy, Filgrastim can accelerate neutrophil recovery, leading to a reduction in duration of the neutropenic phase</td></tr><tr><th>Absorption</th><td>Absorption and clearance of Neupogen follows first-order pharmacokinetic modeling without apparent concentration dependence. When 3.45 mcg/kg and 11.5 mcg/kg of Neupogen is subcutaneously administered, the maximum serum concentration is 4 and 49 ng/mL&#8218; respectively&#8218; within 2 to 8 hours. Neupogen does not accumulate. It is estimated that when filgrastim is subcutaneously administered, the absolute bioavailability is approximately 62% and 71% for 375 mcg and 750 mcg doses respectively. When 5 mcg/kg tbo-filgrastim is subcutaneously administered, the absolute bioavailability is 33%. It takes 4-6 hours for tho-filgrastim to reach maximum concentration. Like Neupogen, accumulation was not observed. </td></tr><tr><th>Volume of distribution</th><td><p>Vd, healthy subjects and cancer patients = 150 mL/kg</p></td></tr><tr><th>Protein binding</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Metabolism</th><td class="data-table-container"></td></tr><tr><th>Route of elimination</th><td>Filgrastim is primarily eliminated by the kidney and neutrophils/neutrophil precursors; the latter presumably involves binding of the growth factor to the G-CSF receptor on the cell surface, internalization of the growth factor-receptor complexes via endocytosis, and subsequent degradation inside the cells. </td></tr><tr><th>Half life</th><td>Elimination half-life, healthy subjects and cancer patients, Neopogen = 3.5 hours;
Elimination half-life, cancer patients, tbo-filgrastim = 3.2-3.8 hours  </td></tr><tr><th>Clearance</th><td><p>0.5 &#8211; 0.7 mL/minute/kg (SC administration of 3.45 mcg/kg and 11.5 mcg/kg in both normal subjects and cancer patients, Neupogen)</p></td></tr><tr><th>Toxicity</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.amgen.com">Amgen Inc.</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Injection, solution</td><td>Intravenous</td><td>300 mcg/mL; 480 mcg/1.6 mL; 300 mcg/0.5 mL; 480 mcg/0.8 mL</td></tr><tr><td>Injection, solution</td><td>Subcutaneous</td><td>300 mcg/0.5 mL; 480 mcg/0.8 mL</td></tr></tbody></table></td></tr><tr><th>Prices</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="prices"><thead><tr><th>Unit description</th><th>Cost</th><th>Unit</th></tr></thead><tbody><tr><td>Neupogen 480 mcg/0.8ml Solution 1 Box Contains Ten 0.8ml Syringes</td><td>4998.24USD</td><td>box</td></tr><tr><td>Neupogen 480 mcg/1.6ml Solution 1 Box Contains Ten 1.6ml Syringes</td><td>4554.58USD</td><td>box</td></tr><tr><td>Neupogen 300 mcg/0.5ml Solution 1 Box Contains Ten 0.5ml Syringes</td><td>3138.1USD</td><td>box</td></tr><tr><td>Neupogen 480 mcg/1.6 ml vial</td><td>437.94USD</td><td>ml</td></tr><tr><td>Neupogen 300 mcg/ml vial</td><td>286.04USD</td><td>vial</td></tr></tbody></table><div class="alert alert-warning clearfix">DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.</div></td></tr><tr><th>Patents</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="patents"><thead><tr><th>Country</th><th>Patent Number</th><th>Approved</th><th>Expires (estimated)</th></tr></thead><tbody><tr><td>Canada</td><td>1341537</td><td>2007-07-31</td><td>2024-07-31</td></tr><tr><td>Canada</td><td>1339071</td><td>1997-07-29</td><td>2014-07-29</td></tr></tbody></table></td></tr><tr id="properties"><th class="divider" colspan="2">Properties</th></tr><tr><th>State</th><td>liquid</td></tr><tr><th>Experimental Properties</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr><tr><td>melting point</td><td>60 &#176;C</td><td>Luo, P., Protein Science 11:1218-1226 (2002)</td></tr><tr><td>hydrophobicity</td><td>0.209</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>isoelectric point</td><td>5.65</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></table></td></tr><tr id="references"><th class="divider" colspan="2">References</th></tr><tr><th>Synthesis Reference</th><td><span class="citations"><p>Tetsuro Kuga, Hiromasa Miyaji, Moriyuki Sato, Masami Okabe, Makoto Morimoto, Seiga Itoh, Motoo Yamasaki, Yoshiharu Yokoo, Kazuo Yamaguchi, Hajime Yoshida, Yoshinori Komatsu, &#8220;Method of producing a polypeptide having human granulocyte colony stimulating factor activity.&#8221; U.S. Patent US5994518, issued February, 1988.</p></span><a class="wishart-link-out" href="https://www.google.com/?tbm=pts#q=5994518&amp;tbm=pts" target="_blank">US5994518 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><th>General Reference</th><td><span class="citations"><ol>
	<li>Wang B, Ludden TM, Cheung EN, Schwab GG, Roskos LK: Population pharmacokinetic-pharmacodynamic modeling of filgrastim (r-metHuG-<span class="caps">CSF</span>) in healthy volunteers. J Pharmacokinet Pharmacodyn. 2001 Aug;28(4):321-42. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11677930">Pubmed</a></li>
	<li><span class="caps">FDA</span> label for Neupogen and tbo-filgrastim</li>
</ol></span></td></tr><tr><th>External Links</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Resource</th><th>Link</th></tr></thead><tbody><tr><td>UniProt</td><td><a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P09919" target="_blank">P09919 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Genbank</td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=X03438" target="_blank">X03438 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PharmGKB</td><td><a class="wishart-link-out" href="http://www.pharmgkb.org/drug/PA449626" target="_blank">PA449626 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drug Product Database</td><td><a class="wishart-link-out" href="http://205.193.93.51/dpdonline/searchRequest.do?din=1968017" target="_blank">1968017 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>RxList</td><td><a class="wishart-link-out" href="http://www.rxlist.com/cgi/generic/filgrastim.htm" target="_blank">http://www.rxlist.com/cgi/generic/filgrastim.htm <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drugs.com</td><td><a class="wishart-link-out" href="http://www.drugs.com/cdi/filgrastim.html" target="_blank">http://www.drugs.com/cdi/filgrastim.html <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Wikipedia</td><td><a class="wishart-link-out" href="http://en.wikipedia.org/wiki/Filgrastim" target="_blank">Filgrastim <span class="glyphicon glyphicon-new-window"> </span></a></td></tr></tbody></table></td></tr><tr><th>ATC Codes</th><td>L03AA02<ul class="atc-drug-tree"><li><a href="/atc/L#L">L &#8212; ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</a></li><li><a href="/atc/L03#L03">L03 &#8212; IMMUNOSTIMULANTS</a></li><li><a href="/atc/L03A#L03A">L03A &#8212; IMMUNOSTIMULANTS</a></li><li><a href="/atc/L03AA#L03AA">L03AA &#8212; Colony stimulating factors</a></li></ul></td></tr><tr><th>AHFS Codes</th><td><ul><li>20:16.00</li></ul></td></tr><tr><th>PDB Entries</th><td><ul><li><a class="wishart-link-out" href="http://www.rcsb.org/pdb/explore.do?structureId=1PGR" target="_blank">1PGR <span class="glyphicon glyphicon-new-window"> </span></a></li></ul></td></tr><tr><th>FDA label</th><td><a href="/system/fda_labels/DB00099.pdf?1265922795">show</a>(769 KB)</td></tr><tr><th>MSDS</th><td><a href="/system/msds/DB00099.pdf?1370764327">show</a>(125 KB)</td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01030">Topotecan</a></td><td>Filgrastim may increase the adverse effects of Topotecan. Increased risk of prolonged neutropenia. Filgrastim should be administered at least 24 hours following Topotecan therapy. Monitor for signs and symptoms of neutropenia. </td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>